Granulocyte Colony-Stimulating Factor in the Combination Chemotherapy for Adult T-Cell Leukemia (ATL)

• Published in: Leukemia & lymphoma 1998-04, Vol.29 (3-4), p.407-414
• Main Authors: Uozumi, Kimiharu, Nakahara, Katsushi, Takatsuka, Yoshifusa, Ohno, Nobuhito, Makino, Torahiko, Utsunomiya, Atae, Hanada, Shuichi, Arima, Terukatsu
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - therapeutic use; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; ATL; Cause of Death; Female; Filgrastim; G-CSF; Granulocyte Colony-Stimulating Factor - therapeutic use; Humans; Lenograstim; Leukemia, Prolymphocytic, T-Cell - drug therapy; Leukemia, Prolymphocytic, T-Cell - mortality; Leukemia-Lymphoma, Adult T-Cell - drug therapy; Leukemia-Lymphoma, Adult T-Cell - mortality; Male; Middle Aged; Neutropenia - therapy; RCM protocol; Recombinant Proteins - therapeutic use; standard-dose chemotherapy
• ISSN: 1042-8194; 1029-2403
• DOI: 10.3109/10428199809068577

We evaluated the effect of granulocyte colony-stimulating factor (G-CSF) on the median survival of 17 patients with Adult T-cell leukemia (ATL). Standard-dose combination chemotherapy using the response-oriented cyclic multidrug (RCM) protocol with G-CSF (lenograstim 2 was administered between October 1990 and December 1994. Complete responses (CR) were achieved in 11 (64.7%) patients, and partial responses (PR) in 4 (23.5%) patients. The median duration of survival was 7.4 months, compared with 6.0 months in ATL patients treated with the RCM protocol alone (historical controls) (n.s.). Infectious complications were the cause of death in 4 (26.7%) of the 15 patients who died. The median duration of neutropenia (absolute neutrophil count < 1.0± 109/L) was 6 days. G-CSF, in the doses and schedules used here, may have shortened the duration of neutropenia and reduced the incidence of fatal infectious complications. However, concomitant use of G-CSF did not prolong the median duration of survival in patients with ATL treated according to the RCM protocol.